The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VIZO-PF BIMATOPROST (AFT Pharmaceuticals Pty Ltd)
Product name
VIZO-PF BIMATOPROST
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
119 working days (255)
Active ingredients
bimatoprost
Registration type
New generic medicine
Indication
VIZO-PF BIMATOPROST (eye drops) is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.